China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd. has successfully passed a resolution regarding the Supplemental Sales Framework Agreement in their 2024 First Extraordinary General Meeting, with a unanimous poll result of 100% in favor. The resolution includes the approval of the Agreement, the transactions, and the Annual Caps involved. Shareholders of the company, particularly those with a controlling interest, abstained from voting to avoid conflicts of interest.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
